HC Wainwright Expects Higher Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Rockwell Medical in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.03 per share for the year, up from their previous estimate of ($0.03). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2024 earnings at $0.02 EPS, Q1 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.03) EPS.

RMTI has been the topic of several other research reports. Rodman & Renshaw began coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They set a “buy” rating and a $5.00 target price on the stock. RODMAN&RENSHAW upgraded Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th. Finally, StockNews.com cut Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st.

Rockwell Medical Stock Down 2.6 %

RMTI stock opened at $2.25 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 2.00. Rockwell Medical has a one year low of $1.16 and a one year high of $5.15. The company’s 50 day moving average price is $3.46 and its two-hundred day moving average price is $2.66.

Institutional Trading of Rockwell Medical

A number of institutional investors have recently modified their holdings of RMTI. Armistice Capital LLC raised its position in Rockwell Medical by 22.5% during the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after purchasing an additional 592,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Rockwell Medical by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after acquiring an additional 43,302 shares in the last quarter. Jane Street Group LLC purchased a new stake in Rockwell Medical in the third quarter worth $534,000. Walleye Capital LLC bought a new stake in Rockwell Medical in the third quarter valued at $435,000. Finally, Renaissance Technologies LLC increased its position in Rockwell Medical by 877.1% during the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after purchasing an additional 92,189 shares during the period. 23.31% of the stock is currently owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.